share_log

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果,顯示與其他FXR激動劑相比,具有顯著的降低肝脂和改善安全性的優勢
Benzinga ·  11/20 08:08

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

Organovo 在肝臟會議上重點介紹了 FXR314 在 MASH 中的第 2 階段結果,與其他 FXR 激動劑相比,顯示肝脂顯著減少且安全性得到改善

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論